Skip to main content
TipRanks
Go Ultimate75% OFF

Halma plc (H11) Q2 2027 Earnings Report

2 Followers

DE:H11 Q2 2027 EPS Results

Actual EPS
EUR 0.79
Consensus EPS
EUR 0.75
Beat/Miss
Beat by +EUR 0.04
One Year Ago EPS
EUR 0.66

DE:H11 Q2 2027 Revenue Results

Actual Revenue
EUR 1.71B
Expected Revenue
EUR 1.70B
Beat/Miss
Beat by +EUR 7.16M
YoY Revenue Growth
+15.82%

Earnings Announcement Details

Quarter
Q2 2027
Date
11/19/2026
Time
Before Open
Conference Call
Thursday, November 19, 2026
DE:H11 Upcoming Earnings

Halma plc's next earnings date is estimated for June 10, 2027, based on past reporting schedules.

Q2 2027 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q2 2027 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2027 Earnings Call Summary

Q2 2027
Earnings Call Date:Nov 19, 2026|% Change Since:0.00%|
Earnings Call Sentiment|Positive

The call was strongly positive, characterized by record first-half revenue and EBIT growth, margin expansion, broad-based performance across all three sectors, exceptional Photonics growth, substantial acquisition and R&D investment, strong returns, and continued dividend growth. Management also highlighted elevated external uncertainty, tougher second-half comparisons, lower-than-target first-half cash conversion, Healthcare Enablement's decline, modest Water Analysis & Treatment growth, and ongoing Photonics hiring and scaling challenges, but maintained full-year guidance and expressed confidence in the group's momentum and long-term growth model.

Company Guidance

For the full year, Halma continues to expect low double-digit percentage organic revenue growth, including approximately 5 percentage points of premium growth from its Photonics business, and adjusted EBIT margin in the range of 23.5% to 24%; Photonics organic revenue growth is expected to be around 30%, which implies mid-teen-digit growth in the second half over the first half, while full-year cash conversion is expected to be in line with the KPI of 90%, translational currency is expected to have a broadly neutral impact for the year as a whole, and the group remains on track for its 24th consecutive year of profit growth and 48th year of dividend increases of 5% or more.

  • Strong Group Revenue and EBIT GrowthFirst-half revenue grew 17% and adjusted EBIT grew 26%, producing an EBIT margin of 24.1%, up 180 basis points year-on-year.
  • Broad-Based Organic Growth Across All Three SectorsOrganic revenue growth was 13%, with 8% before the Photonics premium, ahead of the 5% target and 7.5% ambition. Growth was broadly based across all three sectors and mostly volume-driven, while price increases were typically 1% to 2%.
  • Strong Returns, Cash Generation and Dividend GrowthReturns increased 110 basis points to 17.3%. Cash conversion was 85%, with management expecting it to be in line with the 90% KPI for the full year. The interim dividend increased 7%, keeping the company on track for its 48th year of dividend increases of 5% or more.
  • Record Investment in R&D and AcquisitionsThe group invested a record GBP 64 million in R&D and GBP 516 million in six purpose-aligned acquisitions during the half, following a record FY 2026. Two additional bolt-on acquisitions were completed after the half year-end.
  • Acquisitions and Portfolio Management Added to GrowthAcquisitions contributed 6% to revenue growth and around 10% to profit growth. Disposals reduced revenue growth by 3% and profit growth by 2%, while being slightly accretive to margins. Acquisition profit increased to 9.8%.
  • Safety Sector Delivered Record MarginSafety revenue grew 10% organically and adjusted profit increased 20%, including 11% organic profit growth. The margin rose 120 basis points to a record 28.2%, supported by growth across all four subsectors and all geographies, operational execution, cost control, accretive acquisitions and disposals, and favorable market and product mix.
  • Safety Demand and Innovation Remained StrongWorker safety benefited from strong demand for interlock applications in energy markets, while fire safety and public safety benefited from ongoing new product development. Safety R&D spend was 6% of revenue, and acquisitions contributed 9% of sector profit.
  • Environmental & Analysis Growth AcceleratedExcluding the Nuvonic one-off in 2026, Environmental & Analysis revenue increased 20% organically and sector profit grew 31%, including 23% organic profit growth. The margin increased 160 basis points to 25.2%, supported by strong revenue growth, overhead cost control, accretive acquisitions and disposals, and favorable product and portfolio mix.
  • Environmental Monitoring and Optical Solutions Performed WellEnvironmental monitoring and measurement benefited from strong demand for gas detection and management solutions in APAC and the U.S. Optical Solutions delivered very strong growth, primarily driven by Photonics. Environmental & Analysis R&D spend was 6% of revenue excluding Photonics, and acquisitions contributed 8% of sector profit.
  • Photonics Continued Its Exceptional GrowthPhotonics delivered organic revenue growth of around 30% in the first half, in line with full-year expectations, after revenues more than doubled over the prior two years. The business supports a long-standing hyperscaler customer in the global data center market.
  • Photonics Demand Visibility and Expansion ActivityManagement said rolling purchase orders typically run 6 to 12 months out and indicated that end-market demand drivers remain strong. Incremental footprint expansion and fit-out are underway, while the company continues working with the customer on R&D, engineering and multiple generations of optical circuit switches.
  • Healthcare Continued Its RecoveryHealthcare revenue increased 6% organically and profit rose 15% organically, producing a margin of 23.8%, up 250 basis points. Growth was broad-based across the subsectors and supported by healthy customer demand, strong execution, overhead cost control, accretive acquisitions and disposals, and favorable product and portfolio mix.
  • Healthcare Demand Was Strong in Key ApplicationsDiscovery, Prevention and Diagnostics benefited from demand for vital-signs monitoring and positive trends in eye-health diagnostics. Therapeutic Solutions benefited from strong demand for surgical instrument products. Healthcare R&D spend was 6% of revenue, while acquisitions contributed over 7% to revenue and 11% to profit.
  • Strong Balance Sheet and Capital Allocation CapacityThe group invested over GBP 450 million in the first half while maintaining a strong financial position. R&D and CapEx totaled GBP 91 million, acquisitions net of disposals totaled GBP 298 million, and GBP 57 million was distributed through the dividend. Leverage was 1.26x, within the operating range of up to 2x.
  • M&A Momentum and Pipeline ExpandedThe group completed two stand-alone acquisitions, Dreampath in Healthcare and Pyxis in Environmental & Analysis, along with four bolt-ons during the half. Two further bolt-ons were completed after the half year-end, and management reported a healthy pipeline across all three sectors with a mix of bolt-on and stand-alone opportunities.
  • Continued Investment in Talent and CapabilitiesHalma continued investing in leadership development, its Grow Your Leadership program, and its Catalyst graduate program, which was doubled in size. The company also expanded divisional leadership capacity, dedicated sector M&A teams, group onboarding capabilities and company-level M&A capabilities.
  • Full-Year Guidance MaintainedDespite elevated economic and geopolitical uncertainty, management continued to expect low double-digit percentage organic revenue growth for the full year, including approximately 5 percentage points of premium growth from Photonics. Adjusted EBIT margin guidance remained 23.5% to 24%.
  • Fourth Consecutive Six-Month Period of Growth Across All SectorsManagement stated that all three sectors had grown for the fourth consecutive six-month period, describing this as unusual historically and as evidence of broad-based performance.

DE:H11 Earnings History

DE:H11 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Jun 10, 20272027 (Q4)0.85-0.7――
Nov 19, 20262027 (Q2)0.750.790.6619.71% (+0.13)
Jun 11, 20262026 (Q4)0.680.700.6115.32% (+0.09)
Nov 20, 20252026 (Q2)0.570.660.5128.60% (+0.15)
Jun 12, 20252025 (Q4)0.590.610.5412.36% (+0.07)
Nov 21, 20242025 (Q2)0.510.510.4416.53% (+0.07)
Jun 13, 20242024 (Q4)0.520.540.4911.03% (+0.05)
Nov 16, 20232024 (Q2)0.440.440.423.65% (+0.02)
Jun 15, 20232023 (Q4)0.470.490.421.79% (+0.09)
Nov 17, 20222023 (Q2)0.320.420.3811.25% (+0.04)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed